Welcome to our dedicated page for Voyager Therapeutics SEC filings (Ticker: VYGR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Voyager Therapeutics, Inc. filings document regulatory disclosures for a Nasdaq-listed biotechnology company developing neurotherapeutics for central nervous system diseases. Its Form 8-K reports include quarterly and annual financial results, corporate updates, Regulation FD investor presentations, executive officer transitions and related exhibits covering pipeline and platform information.
Proxy materials describe annual meeting matters such as director elections, advisory executive compensation votes, auditor ratification, charter matters and proposals involving authorized capital. The filing record also identifies Voyager’s common stock, par value and Nasdaq Global Select Market listing, and formalizes governance and capitalization disclosures relevant to its public-company status.
Voyager Therapeutics, Inc. director and President & CEO Alfred Sandrock reported an open-market sale of common stock tied to tax withholding. He sold 14,197 shares of common stock at a weighted average price of $3.79 per share in transactions on February 24, 2026.
The sale was executed under a durable automatic sale instruction adopted on May 12, 2025 to satisfy tax withholding obligations arising from the vesting of restricted stock units on February 21, 2026, and is described as not a discretionary trade. Following these transactions, Sandrock directly holds 484,060 shares of Voyager Therapeutics common stock.
Voyager Therapeutics, Inc. Chief Financial Officer Nathan D. Jorgensen reported an open-market sale of 4,668 shares of common stock at a weighted average price of $3.77 per share. After this non-discretionary sell-to-cover tax transaction, he holds 151,416 shares directly.
Voyager Therapeutics’ Chief Scientific Officer, Carter Todd Alfred, reported an automatic sale of 4,174 shares of common stock at a weighted average price of $3.76 per share.
The shares were sold under a pre-set instruction to cover tax withholding tied to restricted stock units vesting on February 21, 2026, and he continues to hold 145,718 shares directly.
Notice of proposed resale under Rule 144 by a holder associated with restricted stock vesting. The filing lists a planned sale of 4,174 common shares tied to restricted stock vesting on 02/20/2026. It also reports two completed dispositions in the prior three months: 3,525 shares on 02/10/2026 and 3,301 shares on 02/18/2026, each attributed to Todd Carter. Fidelity Brokerage Services LLC is shown as the broker.
VYGR reports a planned sale of 6,458 common shares under Rule 144 tied to restricted stock vesting on 02/20/2026.
The filing also discloses prior dispositions by Robin E. Swartz in the past three months: 4,569 shares sold on 02/10/2026 for $17,598.87 and 3,882 shares sold on 02/18/2026 for $13,349.03. The planned sale is labeled as Issuer and linked to Compensation (restricted stock vesting).
VYGR reports a restricted stock vesting of 14,197 common shares effective 02/20/2026.
The filing also discloses recent open‑market dispositions by Alfred W. Sandrock Jr.: 12,192 shares sold on 02/10/2026 for $46,093.08 and 11,732 shares sold on 02/18/2026 for $40,038.97.
Voyager Therapeutics, Inc. executive Robin Swartz, the company’s COO & CBO, reported an open-market sale of 3,882 shares of common stock at a weighted average price of $3.44 per share on February 18, 2026. The sale was made under a pre-established durable automatic sale instruction adopted on May 12, 2025 to cover tax withholding obligations tied to restricted stock units that vested on February 17, 2026, and is described as non-discretionary. Following this transaction, Swartz directly owned 206,196 common shares of Voyager Therapeutics.
Voyager Therapeutics, Inc. Chief Scientific Officer Carter Todd Alfred reported an automatic open-market sale of 3,301 shares of common stock at a weighted average price of $3.44 per share. The shares were sold under a pre-established durable automatic sale instruction adopted on May 12, 2025 to cover tax withholding obligations arising from the vesting of restricted stock units on February 17, 2026, and are described as not being a discretionary trade. Following this transaction, Alfred directly holds 149,892 shares of Voyager Therapeutics common stock.
Voyager Therapeutics, Inc. President and CEO Alfred Sandrock reported an open-market sale of 11,732 shares of common stock of Voyager Therapeutics at a weighted average price of $3.41 per share. According to the disclosure, this transaction was executed under a durable automatic sale instruction adopted on May 12, 2025.
The shares were sold to cover tax withholding obligations arising from the vesting of restricted stock units on February 17, 2026, and the filing states that the sale did not represent a discretionary trade by the reporting person. After this tax-related sale, Sandrock directly holds 498,257 shares of Voyager Therapeutics common stock.